文献速递胸部肿瘤乳腺癌消化系统肿瘤

德曲妥珠单抗治疗携带特定激活型HER2突变的实体瘤患者(DESTINY-PanTumor01):一项国际2期研究

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
PubMed 文献 · Lancet Oncol · 2024-05-03

这项开放标签、2期篮式研究在亚洲、欧洲和北美的29个中心纳入102例携带特定激活型HER2突变的不可切除或转移性实体瘤患者,接受德曲妥珠单抗5.4 mg/kg每3周静脉输注。独立中心审查确认的客观缓解率为29.4%(95%CI 20.8-39.3;102例中30例)。≥3级治疗中出现的不良事件发生于52例(51%)患者,最常见的为贫血(16例[16%])和中性粒细胞计数降低(8例[8%])。

要点

  • 德曲妥珠单抗在携带激活型HER2突变的经治实体瘤中客观缓解率为29.4%(95%CI 20.8-39.3)。
  • ≥3级治疗中出现的不良事件发生于52例(51%)患者,最常见为贫血16例(16%)。
  • 任何级别经裁定的药物相关间质性肺病或肺炎发生于11例(11%),其中致死性2例(2%)。

核心结论

  • 德曲妥珠单抗在多种携带激活型HER2突变的经重度治疗肿瘤类型中显示出抗肿瘤活性和持久缓解,未发现新的安全性信号。
  • 预设的HER2突变可能成为HER2靶向抗体药物偶联物的靶点,研究结果支持在泛肿瘤背景下进一步研究德曲妥珠单抗。

研究设计与样本

  • 开放标签、2期篮式研究,在亚洲、欧洲和北美的29个中心开展。
  • 纳入年龄18岁及以上、携带特定激活型HER2突变的不可切除或转移性实体瘤患者,美国东部肿瘤协作组体能状态评分为0或1,既往治疗后疾病进展(允许既往接受HER2靶向治疗)或无满意替代治疗选择。
  • 德曲妥珠单抗5.4 mg/kg每3周静脉输注。
  • 主要终点为独立中心审查确认的客观缓解率;抗肿瘤活性和安全性在所有至少接受一剂德曲妥珠单抗的患者中分析。
  • 2020年12月30日至2023年1月25日期间,102例患者(62例[61%]女性、40例[39%]男性;中位年龄66.5岁[IQR 58-72];51例[50%]白人、2例[2%]黑人或非裔美国人、38例[37%]亚洲人、11例[11%]未报告种族信息)接受德曲妥珠单抗并纳入抗肿瘤活性和安全性分析集。

主要发现

  • 独立中心审查确认的客观缓解率为29.4%(95%CI 20.8-39.3;102例中30例)。
  • 52例(51%)患者发生≥3级治疗中出现的不良事件,最常见(≥5%患者)为贫血(16例[16%])和中性粒细胞计数降低(8例[8%])。
  • 药物相关治疗中出现的严重不良事件发生于10例(10%)患者。
  • 经裁定的药物相关任何级别间质性肺病或肺炎发生于11例(11%;3例1级、5例2级、1例3级、2例5级);致死性经裁定药物相关间质性肺病或肺炎2例(2%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate approved by the US Food and Drug Administration and the European Medicines Agency for HER2-mutant non-small-cell lung cancer. Few treatment options exist for patients with HER2-mutant solid tumours beyond lung cancers. We investigated trastuzumab deruxtecan in metastatic solid tumours with specific activating HER2 mutations. METHODS: In this open-label, phase 2, basket study done in 29 centres in Asia, Europe, and North America, we investigated trastuzumab deruxtecan (5·4 mg/kg every 3 weeks by intravenous infusion) in patients aged 18 years or older with unresectable or metastatic solid tumours with specific activating HER2 mutations, an Eastern Cooperative Oncology Group performance status of 0 or 1, and disease progression following previous treatment (previous HER2-targeted therapy was permitted) or with no satisfactory alternative treatment options. The primary endpoint was confirmed objective response rate by independent central review. Anti-tumour activity and safety were analysed in all patients who received at least one dose of trastuzumab deruxtecan. This trial is registered with ClinicalTrials.gov, NCT04639219, and is active but no longer recruiting. FINDINGS: Between Dec 30, 2020, and Jan 25, 2023, 102 patients (62 [61%] female and 40 [39%] male; median age 66·5 years [IQR 58-72]; 51 [50%] White, two [2%] Black or African American, 38 [37%] Asian, and 11 [11%] did not have race information reported) with solid tumours with activating HER2 mutations received trastuzumab deruxtecan and were included in the anti-tumour activity and safety analyses sets. Patients had a median of three (IQR 2-4) previous treatment regimens. The median duration of follow-up was 8·61 months (IQR 3·71-12·68). The objective response rate by independent central review was 29·4% (95% CI 20·8-39·3; 30 of 102 patients). 52 (51%) patients had a treatment-emergent adverse event of grade 3 or worse; the most common events (in ≥5% of patients) were anaemia (16 [16%]) and neutrophil count decreased (eight [8%]). Drug-related treatment-emergent serious adverse events occurred in ten (10%) patients. Adjudicated drug-related interstitial lung disease or pneumonitis of any grade occurred in 11 patients (11%; three grade 1, five grade 2, one grade 3, and two grade 5); there were two (2%) cases of fatal adjudicated drug-related interstitial lung disease or pneumonitis. INTERPRETATION: Trastuzumab deruxtecan showed anti-tumour activity and durable responses in heavily pretreated patients across multiple tumour types with activating HER2 mutations, with no new safety signals. Prespecified HER2 mutations might be targeted by HER2-directed antibody-drug conjugates and our findings support further investigation of trastuzumab deruxtecan in the pan-tumour setting. FUNDING: AstraZeneca and Daiichi Sankyo.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Li BT, Meric-Bernstam F, Bardia A, et al. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 2024. PMID: 38710187. doi:10.1016/S1470-2045(24)00140-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。